Pharmacogenetics of Cannabinoid Response

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2014 by Yale University
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Deepak C. D'Souza, Yale University
ClinicalTrials.gov Identifier:
NCT00678730
First received: May 13, 2008
Last updated: September 24, 2014
Last verified: September 2014

May 13, 2008
September 24, 2014
July 2007
July 2015   (final data collection date for primary outcome measure)
Behavioral Measures [ Time Frame: Baseline, +15, +25, +60, +300 ] [ Designated as safety issue: No ]
PANSS: Psychotic symptoms will be measured using the Positive and Negative Syndrome Scale (PANSS). Rey Auditory Verbal Learning Test (AVLT): a 15 word list learning task of verbal memory and hippocampal function that has 6 alternate versions. [ Time Frame: Baseline, +15, +25(RAVLT only), +60, +300 ] [ Designated as safety issue: Yes ]
Complete list of historical versions of study NCT00678730 on ClinicalTrials.gov Archive Site
Not Provided
CADSS:scale that measures perceptual alterations.Visual Analog Scale: a 16-item feeling state scale associated with cannabis.CANTAB: a computerized cognitive test battery is used to measure attention and memory. [ Time Frame: Baseline, +15, +35 (CANTAB only), +60, +300 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Pharmacogenetics of Cannabinoid Response
Pharmacogenetics of Cannabinoid Response

This study attempts to examine genetic influences on the effects of tetrahydrocannabinol (Δ9-THC), the active ingredient of marijuana, cannabis, "ganja", or "pot".

Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Basic Science
COMT Gene Polymorphism
Drug: delta 9 tetrahydrocannabinol
0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
Other Names:
  • Marijuana
  • cannabis
  • Active Comparator: 1
    • Very low dose (0.005 mg/kg = 0.35 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/10th of a marijuana cigarette, or "joint".
    • Low dose (0.025 mg/kg = 1.75 mg in a 70kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1/2 of a marijuana cigarette, or "joint".
    • Medium dose (0.05 mg/kg = 3.5 mg in a 70 kg individual) THC, dissolved in ethanol. This dose is roughly equivalent to smoking 1 marijuana cigarette, or "joint".
    Intervention: Drug: delta 9 tetrahydrocannabinol
  • Placebo Comparator: 2
    small amount of ethanol, (quarter teaspoon), with no THC
    Intervention: Drug: delta 9 tetrahydrocannabinol
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
162
July 2015
July 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • 18 and 55 years (extremes included) on the day of the first dosing.

Exclusion Criteria:

  • Cannabis naïve individuals.
Both
18 Years to 55 Years
Yes
Contact: Brynn Huguenel, B.A. 203-932-5711 ext 4650 brynn.huguenel@yale.edu
Contact: Christina Luddy, B.S. 203-932-5711 ext 4549 christina.luddy@yale.edu
United States
 
NCT00678730
0706002754, R01 DA 012382-05
Not Provided
Deepak C. D'Souza, Yale University
Yale University
National Institute on Drug Abuse (NIDA)
Principal Investigator: Deepak D'Souza, M.D. Yale University
Yale University
September 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP